Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.

Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and ...

A decision from the FDA on once-monthly maintenance dosing of Leqembi in early Alzheimer's is expected by Jan. 25, 2025.

A novel technique that detects DNA from dead nerve cells in the blood may help to diagnose Alzheimer's disease, according to a new study.

Among people with a genetic form of Alzheimer's disease, those with more formal education tend to be older at disease onset, a study says.

Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.

An FDA advisory committee has unanimously voted that trial data support the clinical benefits of Leqembi for early Alzheimer's disease.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.

Foralumab helped to normalize microglial cell activity - tied to Alzheimer's progression - in the mice, leading to signs of better cognition.

Posit Science, which produces the BrainHQ app, is collaborating with the YMCA to establish a model community program for dementia prevention.